Impact of high neutrophil‐to‐lymphocyte ratio on survival in hospitalized cancer patients with COVID‐19. (13th November 2022)

• Record Type: Journal Article
• Authors: Díaz‐Couselo, Fernando A.; Flagel, Santiago; Nicolini, Carla; Halac, Sebastián; Manzano, Natalia; Aguirre, Marina; Rébora, Juan; Valle, Sandra; Noro, Laura; Mohindroo, Chirayu; McAllister, Florencia; Zylberman, Marcelo
• Is Part Of: Cancer medicine. Volume 12:Number 6(2023)
• Page Start: 7164
• Page End: 7169
• Publication Date: 2022-11-13
• Subjects: biomarkers -- cancer -- COVID‐19 -- inflammatory markers -- neutrophil lymphocyte ratio -- neutrophils -- NLR; 616.994005
• DOI: 10.1002/cam4.5426
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Neutrophil‐to‐lymphocyte ratio (NLR) has been studied as a prognostic factor for mortality in COVID‐19 patients. Our study aimed to evaluate the association between NLR at COVID‐19 diagnosis and survival during the following 90 days in hospitalized patients with solid cancer. Between May 2020 and June 2021, 120 patients were included in a retrospective cohort study. Univariable analysis showed patients with an NLR > 8.3 were associated with an increased risk of death (HR: 4.34; 95% CI: 1.74–10.84) compared to patients with NLR < 3.82 and with NLR ≥3.82 and ≤8.30 (HR: 2.89; 95% CI: 1.32–6.36). Furthermore, on multivariable analysis, NLR > 8.30 independently correlated with increased mortality. In patients with solid malignancies with COVID‐19, an NLR > 8.3 is associated with an increased risk of death. Abstract : In patients with solid malignancies hospitalized with COVID‐19, an elevated NLR at hospital admission may be predictive of increased risk of death.